Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEJH-RE-06Cat.No.:HY-126214CASNo.:1361227-90-8分?式:C??H??Cl?N?O?分?量:468.72作?靶點:DNA/RNASynthesis作?通路:CellCycle/DNADamage儲存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數據體外實驗DMSO:5mg/mL(10.67mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.1335mL10.6673mL21.3347mL5mM0.4267mL2.1335mL4.2669mL10mM0.2133mL1.0667mL2.1335mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內使?，-20°C儲存時，請在1個?內使?。BIOLOGICALACTIVITY?物活性JH-RE-06,有效的REV1-REV7互作抑制劑(IC50=0.78μM;Kd=0.42μM)，靶向與POLζ的REV7亞相互作?的REV1。JH-RE-06通過阻?誘變POLζ的募集來破壞誘變性跨損傷合成(TLS)。JH-RE-06可改化療效果[1][2]。IC50&TargetIC50:0.78μM(REV1-REV7)[1]Kd:0.42μM(REV1-REV7)[1]1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE體外研究JH-RE-06unexpectedlyinducesdimerizationoftheREV1CTDatitsREV7-bindingsurfaceandblockstheREV1-REV7interaction[1].體內研究JH-RE-06inhibitsmutagenicTLSandenhancescisplatin-inducedtoxicityinculturedhumanandmousecelllines[1].Co-administrationofJH-RE-06withcisplatinsuppressesthegrowthofxenografthumanmelanomasinmice[1].REFERENCES[1].WojtaszekJL,etal.ASmallMoleculeTargetingMutagenicTranslesionSynthesisImprovesChemotherapy.Cell.2019Jun27;178(1):152-159.e11.[2].REV1-POL?InhibitionEnhancesCisplatin-InducedCytotoxicity.CancerDiscov.2019Aug;9(8):OF17.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792;021-589559